Can the ADO Index Be Used as a Predictor of Mortality from COVID-19 in Patients with COPD?

Basit Öğe Kaydı
dc.authoridSarioglu, Nurhan/0000-0002-5180-9649
dc.authoridOgan, Nalan/0000-0001-5232-3803
dc.contributor.authorYazar, Esra Ertan
dc.contributor.authorGunluoglu, Gulsah
dc.contributor.authorYigitbas, Burcu Arpinar
dc.contributor.authorCalikoglu, Mukadder
dc.contributor.authorGulbas, Gazi
dc.contributor.authorSarioglu, Nurhan
dc.contributor.authorBozkus, Fulsen
dc.date.accessioned2024-08-04T20:55:55Z
dc.date.available2024-08-04T20:55:55Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Several studies have shown that the risk of mortality due to COVID-19 is high in patients with COPD. However, evidence on factors predicting mortality is limited. Research Question: Are there any useful markers to predict mortality in COVID-19 patients with COPD?. Study Design and Methods: A total of 689 patients were included in this study from the COPET study, a national multicenter observational study investigating COPD phenotypes consisting of patients who were followed up with a spirometry-confirmed COPD diagnosis. Patients were also retrospectively examined in terms of COVID-19 and their outcomes. Results: Among the study patients, 105 were diagnosed with PCR-positive COVID-19, and 19 of them died. Body mass index (p= 0.01) and ADO (age, dyspnoea, airflow obstruction) index (p= 0.01) were higher, whereas predicted FEV1 (p< 0.001) and eosinophil count (p= 0.003) were lower in patients who died of COVID-19. Each 0.755 unit increase in the ADO index increased the risk of death by 2.12 times, and each 0.007 unit increase in the eosinophil count decreased the risk of death by 1.007 times. The optimum cut-off ADO score of 3.5 was diagnostic with 94% sensitivity and 40% specificity in predicting mortality. Interpretation: Our study suggested that the ADO index recorded in the stable period in patients with COPD makes a modest contribution to the prediction of mortality due to COVID-19. Further studies are needed to validate the use of the ADO index in estimating mortality in both COVID-19 and other viral respiratory infections in patients with COPD.en_US
dc.identifier.doi10.2147/COPD.S440099
dc.identifier.endpage858en_US
dc.identifier.issn1178-2005
dc.identifier.pmid38596202en_US
dc.identifier.scopus2-s2.0-85190472054en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage851en_US
dc.identifier.urihttps://doi.org/10.2147/COPD.S440099
dc.identifier.urihttps://hdl.handle.net/11616/101936
dc.identifier.volume19en_US
dc.identifier.wosWOS:001197888000001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherDove Medical Press Ltden_US
dc.relation.ispartofInternational Journal of Chronic Obstructive Pulmonary Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbody mass indexen_US
dc.subjectCOVID-19en_US
dc.subjecteosinophilsen_US
dc.subjectFEV1en_US
dc.subjectmortalityen_US
dc.subjectpneumoniaen_US
dc.subjectpulmonary diseaseen_US
dc.subjectchronic obstructiveen_US
dc.titleCan the ADO Index Be Used as a Predictor of Mortality from COVID-19 in Patients with COPD?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu